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Neuropathic pain (NP) is a highly invalidating disease resulting as consequence of a lesion or disease affecting the somatosensory
system. All the pharmacological treatments today in use give a long lasting pain relief only in a limited percentage of patients
before pain reappears making NP an incurable disease. New approaches are therefore needed and research is testing stem cell
usage. Several papers have been written on experimental neuropathic pain treatment using stem cells of different origin and species
to treat experimental NP. The original idea was based on the capacity of stem cell to offer a totipotent cellular source for replacing
injured neural cells and for delivering trophic factors to lesion site; soon the researchers agreed that the capacity of stem cells to
contrast NP was not dependent upon their regenerative effect but was mostly linked to a bidirectional interaction between the
stem cell and damaged microenvironment resident cells. In this paper we review the preclinical studies produced in the last years
assessing the effects induced by several stem cells in different models of neuropathic pain. The overall positive results obtained on
pain remission by using stem cells that are safe, of easy isolation, and which may allow an autologous transplant in patients may be
encouraging for moving from bench to bedside, although there are several issues that still need to be solved.
1. Introduction
Neuropathic pain (NP), currently defined as “pain arising
as a direct consequence of a lesion or disease affecting
the somatosensory system” [1], represents the most severe
form of chronic pain considering its capacity to affect both
physical and mental patient’s condition. The nature of NP
is extremely heterogeneous and four main categories of
neuropathic lesions have been recognized: focal or multifocal
lesions of the peripheral nervous system (PNS), lesions of
the central nervous system (CNS), polyneuropathies, and
complex neuropathic disorders [2]. Regardless of the primary
etiology, NP can present itself as spontaneous pain sensations
such as paroxysmal pain (shooting pain) and superficial pain
(burning sensation) or as evoked pain: mechanical/thermal
allodynia (pain caused by normally nonpainful mechani-
cal or thermal stimuli), hyperalgesia (increased sensitivity
to a normally painful stimulus), or temporal summation
(increasing pain sensation from repetitive application of the
identical stimulus) [3]. It has recently been pointed out
that neuropathic pain pathogenesis and maintenance involve
interactions among neurons, inflammatory immune cells,
glial cells, and a wide cascade of pro- and anti-inflammatory
cytokines [4–7]. One of the main problems concerning NP
regards its scarce response to the conventional analgesic ther-
apy. Drugs, mainly represented by tricyclic antidepressant,
calcium channel ligands, SSNRI, and opioids, are in fact not
fully effective and their efficacy decreases over time with
development of tolerance in long termuse [8, 9]. It is therefore
mandatory to identify and propose novel approaches to NP
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treatment that could overcome many of the limitations of the
available strategies.
In the last yearsmany researchers, including us, have tried
to relieve neuropathic pain by using stem cells of different
origin. The first moving idea was based on the capacity of
stem cell to offer a multipotent cellular source for replacing
injured or lost neural cells and for delivering trophic factors
to lesion site; in this way, stem cells can represent not only a
pain treatment but a way for repairing the damaged nervous
system at the basis of NP development. Soon we and others
realized that the capacity of stem cells to contrast exper-
imental neuropathic pain was not completely dependent
upon their regenerative effect; in fact many research papers
described an antinociceptive effect of the stem cell achieved
before the appearance of regenerative effect [10]. In this paper
we review the literature in which stem cells of different origin
and species were used to treat neuropathic pain induced in
experimental animal models. We divide the published papers
according to the type of stem cell used, independently of
the experimental NP model. We do not report the studies
with embryonic stem cells considering the associated ethical
problem and the major risk of tumors correlated to them.
Moreover, we considered only papers in which the effect of
stem cells on pain behaviour has been specifically evaluated.
Today there are three main types of stem cells used for
neuropathic pain: neural stem cells, mesenchymal stem cells,
and bone marrow mononuclear cells.
2. Neural Stem Cells
Considering the nature of the lesion at the basis of NP
development that takes place in PNS or CNS, neural stem
cells (NSCs) seem to be the most appropriate type of
cells to prompt a physiological repair of the lesion, due to
their capacity to differentiate into neurons, astrocytes, and
oligodendrocytes, even though it was suggested that also
mesenchymal stem cells, under particular conditions, can
originate cells of the neural lineage [11–13]. Neural stem
cells were identified for the first time and isolated from
the subventricular zone of adult mammalian brain in 1992
[14, 15]. They are multipotential precursors that grow and
self-renew in culture for an extensive period of time as
neurospheres, while retaining a stable capacity to generate
mature functional brain cells. So far, NSC lines have been
derived from the hippocampal dentate gyrus, the olfactory
bulb, the SVZ surrounding the ventricles, the subcallosal zone
underlying the corpus callosum, and the spinal cord of the
embryonic, neonatal, and adult rodent CNS [15], as well as
from human fetal CNS [16–18].
Our group [10] described for the first time the use
of intravenous murine neural stem cells, NSCs, to treat
neuropathic pain which develops as consequence of a lesion
of the peripheral nervous system, that is, sciatic nerve chronic
constriction injury (CCI). Cells, isolated from the subventric-
ular zone using the neurosphere technique [19], were treated
to express GFP gene thus allowing their localization after
transplant. Even though efficiency of the transplant is low, we
described the rapid and specific homing ofNSC to the injured
nerve, since these cellswere present at lesion site starting from
day 1 to day 7 after injection. Their short time presence at
lesion site was, however, able to start a cascade of events in
themain sites of pain transmission, which contributed to pain
reduction.
Regarding their effects on pain relief, NSC, injected when
the pathology was already established, induced a significant
reduction in allodynia and hyperalgesia already 3 days after
administration, demonstrating a therapeutic effect that lasted
for at least 28 days. Responses changed with the number of
administered NSCs and the effect on hyperalgesia could be
boosted by a new NSC administration. Treatment induced
changes in cytokine profile at lesion site, decreasing signif-
icantly the proinflammatory cytokine Interleukin-1 both as
mRNA and protein, while cells were unable to normalize
the levels of the anti-inflammatory cytokine IL-10 decreased
by CCI. The effect on pain relief was also demonstrated
by a reduction of spinal cord Fos expression in laminae
I–VI. Moreover we observed a reparative process and an
improvement of nerve morphology, due to NSC treatment,
which was present at a later time, when pain was already
controlled by NSC treatment. Since NSC effect on pain
symptoms preceded nerve repair and was maintained after
cell disappearance from the lesion site, we believe that the
regenerative, behavioral, and immune NSC effects are largely
due to microenvironmental changes that they might induce
in the lesion. Our results support the idea of a general
bystander effect exerted by transplanted NSC [20]. These
positive results on neuropathic pain relief were supported
by Xu and colleagues [21] by using another route for NSC
administration; the authors described that an intrathecal
administration of neural stem cells, 3 days after CCI injury
in rat, was able to significantly attenuate mechanical and
thermal hyperalgesia with a marked increase of protein and
mRNA levels of glial cell line derived neurotrophic factor
(GDNF) in the spinal dorsal horn and dorsal root ganglia
(DRG). So far we have considered the use of NSC for treating
NP which follows a peripheral lesion of the nervous system;
however, neural progenitors/stem cells were also used to
treat lesions at spinal cord level. One of the main problems
concerning their use in these conditions is represented by
their low survival in the host damaged spinal cord. For this
reason combinatorial strategies were developed to try to
improve their transplant efficiency but the final outcome on
NP is questionable. Positive results on pain were obtained by
the group of Luo [22] investigating the efficacy of a cotrans-
plantation of NSC and OECs (olfactory ensheathing cells) in
a rat spinal cord transection injury model. They found that
the transplantation of NSC together withOEC could improve
the sensory function to mechanical and thermal stimuli
after SCI; the authors suggested that OECs can promote the
NSC survival and the cotransplantation downregulates the
expression of NGF. Karimi-Abdolrezaee et al. [23] instead
developed a combinatorial strategy that allows the successful
application of neural progenitor cells (NPC) based therapies
for the treatment of chronic spinal cord injury. The authors
showed that chondroitin sulfate proteoglycans (CSPGs) in
the glial scar around the site of chronic SCI negatively influ-
ences the long-term survival and integration of transplanted
NPC and their therapeutic potential. For this reason they
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targeted CSPGs and one week later treated the same rats
with transplants of NPC and transient infusion of growth
factors (EGF, bFGF, and PDGF-AA). This combinatorial
approach markedly increased the long-term survival of NPC
and greatly optimized their migration and integration in the
chronically injured spinal cord. Furthermore, this combined
strategy promoted the axonal integrity and plasticity of the
corticospinal tract and enhanced the plasticity of descending
serotonergic pathways. These neuroanatomical changes were
also associated with significantly improved neurobehavioral
recovery after chronic SCI. However, cells were unable to
modify the development of allodynia which follows the tho-
racic spinal cord injury. It is important to report that the first
papers trying stem cell approaches in SCI models described
negative results for pain relief. Hofstetter and colleagues [24]
suggested a correlation between induction of allodynia after
SCI and the transplantation ofNPC.They reported that trans-
planted naive NPCs primarily differentiate into astrocytes
and this was associated with induced aberrant sprouting of
Calcitonin gene related peptide fibers rostral to the injury,
leading to increased allodynia. In the same years, Macias et
al. described that NSC primarily differentiated into astrocytes
when transplanted into the injured spinal cordwhich resulted
in thermal and mechanical forelimb allodynia [25].
All the papers mentioned above described the use of neu-
ral precursors/stem cells isolated from rodents; in literature,
to our knowledge, there is only one paper which showed
the results of using human neural stem cells in experimental
animal models of NP. In this paper human neural stem cells
are shown to be capable of surviving and differentiating in a
traumatically injured environment improving the locomotor
recovery [26]. However, in experimental paradigms of other
pathologies, human neural stem cells (hNSC) have revealed
anti-inflammatory and therapeutic abilities analogous to
their murine counterpart [27–29]. Moreover, the possibility
to isolate and expand hNSC lines of clinical grade [18] has
allowed evaluating the safety of these cells in a phase I
clinical trial in amyotrophic lateral sclerosis patients, which
is currently underway.
3. Mesenchymal Stem Cells (MSC)
MSC are a heterogeneous subset of stromal stem cells which
can be isolated from different sources: bone marrow [30],
umbilical cord (UC) [31, 32], placenta [33], adipose tissue
[34], dental pulp [35], and even the fetal liver [36] and
lungs [37]. These cells express typical surface markers such
as CD73, CD44, CD90, and CD105. Among MSC, the most
representative ones are bone marrow MSC (BMSC), purified
from bone marrow, and adipose tissue derived MSC (ASC),
isolated from adipose tissue. ASCs are described to be BMSC
migrated into the adipose tissue; hence there are no marked
phenotypic differences between these two cell types [34, 38].
However, in recent years, other types of MSC, such as those
derived fromumbilical cord blood (UCB-MSC) and amniotic
mesenchymal stem cells, have begun to attract researchers’
attention for their therapeutic use.
A basic description of bone marrow may help clarify
the origin of bone marrow derived mesenchymal stem
cells. Bone marrow consists of a hematopoietic compo-
nent (parenchyma) and a vascular component (stroma).
The parenchyma includes hematopoietic stem cells and
hematopoietic progenitor cells while bone marrow stroma
contains multipotent nonhematopoietic progenitor cells,
bone marrow stromal cells (MSC) that are known as multi-
potent cells capable of differentiating under specific exper-
imental conditions into several types of cells, for example,
osteoblasts, chondrocytes, adipocytes, and myocytes [30].
Moreover, some papers described the capacity of MSC to
transdifferentiate also into neurons or astrocytes [11–13]. Both
rodent and humanMSC and bonemarrowmononuclear cells
were used for treating experimental neuropathic pain.
3.1. Bone Marrow MSC (BMSC)
3.1.1. Rodent BMSC. One of the first groups to assess the
effect of rat bone marrow stromal cells in an experimental rat
model of peripheral neuropathy was the group of Musolino
[39]. They demonstrated that an ipsilateral intraganglionic
injection of rat bonemarrow stromal cells was able to prevent
the generation of mechanical allodynia and to reduce the
number of allodynic responses to cold stimuli in rats that
underwent a single ligature sciatic nerve constriction [39].
One of the possible mechanisms involved in such effect was
the capacity of BMSC to partially prevent the injury-induced
changes in galanin, Neuropeptide Y and Neuropeptide Y
receptor expression in DRG [40]. The authors compared the
effect of MSC on pain relief and biochemical changes to that
of bone marrow nonadherent mononuclear cells (BNMCs),
but these latter stem cells were, in that case, unable to reduce
pain [39].
Rat bone marrow MSC has also been used in another
type of neuropathic pain treatment, not derived from a direct
nerve lesion, but consequence of the metabolic dysfunction
present in diabetes which is one of the main causes of painful
neuropathy in human. Shibata and colleagues tried in fact
to improve diabetic polyneuropathy induced in rat by using
Streptozotocin (STZ) [41]. MSC (1 × 106) were therapeutically
injected into the hind limb muscle 8 weeks after diabetes
induction. The authors described an increase in VEGF and
bFGF mRNA expression in MSC-injected diabetic rats and
colocalized VEGF and bFGF in MSC in the transplanted site
thus suggesting that MSC are responsible for growth factors
secretion at the injected site. MSC were able to ameliorate
all the alterations induced by diabetes such as hypoalgesia,
delayed nerve conduction velocity, and decreased sciatic
nerve blood flow. Moreover, MSC transplantation was able
to normalize sural nerve morphometry restoring the axonal
circularity, decreased in diabetic rats. The same positive
effect on nerve conduction velocity amelioration was also
reported by Kim and Jin [42], using the same model of
diabetic neuropathy in mice, by injecting murine MSC into
the hind limb muscle percutaneously along the course of the
sciatic nerve at 4 sites.The improvement in nerve conduction
velocity was attributed to the ability of MSC to increase
trophic factors specific for neuronal populations in the PNS
such as nerve growth factor (NGF) and neurotrophin-3 (NT-
3). The authors did not directly assess pain.
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Figure 1: Time course of the effect of murine neural stem cells (NSCs) and human adipose derived stem cells (hASC) on thermal hyperalgesia
(a), measured by Plantar test, and mechanical allodynia, measured by Dynamic Plantar Aesthesiometer (b), in neuropathic mice. 1 × 106
NSCs/ASCs were injected intravenously 7 days after mice chronic constriction injury; their effect on pain was measured 3, 7, 14, and 21 days
after the administration. Data represent mean +/− SEM of 7 mice. The statistical analysis was performed by using the two-way ANOVA
analysis of variance followed by Bonferroni test. ∗𝑃 < 0.001 versus Sham, ∘𝑃 < 0.001 versus CCI, and #𝑃 < 0.001 versus hASC.
3.1.2. h(Human)BMSC. TheMaione’s group is the main user
of human BMSC for treating experimental neuropathic pain.
The authors use, as model of NP, the spared nerve injury
(SNI) model in mice and administer hBMSC therapeutically,
that is, 4 days after the surgery, injecting them either in the
mouse lateral cerebral ventricle [43] or systemically into the
caudal vein [44].When intravenously injected, cells were able
to home into the spinal cord and prefrontal cortex of SNI
neuropathic mice. In both papers, hBMSC reduced pain-
like behaviors, such as mechanical allodynia and thermal
hyperalgesia, with an effect which was evident one week
after cell transplantation and was long lasting. Indeed, when
cells were injected into the caudal vein, their effect on pain
relief was still present three months after transplant. The
authors described the capacity of these cells to reduce glial
[43] and macrophage activation [44] switching to an anti-
inflammatory phenotype by decreasing the proinflammatory
cytokines (IL-1 beta and IL-17) and increasing the anti-
inflammatory cytokine IL-10 [43, 44].
The group ofWaterman [45] developed amethod to opti-
mize the anti-inflammatory effects of human bone marrow
MSC, skewing them in vitro, before their injections, towards
a protective MSC2 phenotype. These MSC demonstrated a
higher capacity to counteract mechanical allodynia and heat
hypoalgesia induced in mice by STZ treatment. These cells
were also able to decrease the serum level of proinflammatory
cytokines and were described to be safe.
3.2. Adipose Tissue Derived MSC (ASC). The great advantage
of these cells, over the other kinds of MSC, is given by the
possibility of isolating themby using low invasive procedures.
These cells are in fact located inmature subcutaneous adipose
tissue and can be obtained as litter of the fatty tissue
after liposuction; the use of this tissue allows to obtain a
large amount of MSC thus reducing, in some cases, the
need of ex vivo culturing, leading eventually to lower the
risk of developing chromosomal abnormalities due to the
culture itself. Moreover, these cells are characterized by low
immunogenicity and by high immunomodulatory properties
which make them suitable for treating diseases in which the
neuroinflammatory component plays a crucial role, such as
NP. Not least these cells might be easily used for autologous
transplant. Despite the high potential of these cells, their use
for experimental neuropathic pain treatment is still limited.
Our paper, recently published [46], was the first to assess
the antinociceptive effect of hASC isolated from human
adipose tissue of female donors undergoing plastic surgery.
This paper is a complete work in which safety, antinociceptive
effects, and biochemical changes induced by these cells were
assessed. hASC were in vitro expanded [47, 48] and, after
karyotype assessment, were injected into the caudal vein of
neuropathic mice (CCI mice). Cells were injected, with a
therapeutic intent, seven days after the surgery, in presence
of a fully developed thermal hyperalgesia and mechanical
allodynia. We clearly demonstrated a rapid, long lasting,
and dose dependent antihyperalgesic and antiallodynic effect
which could be reestablished with a second dose of cells
when it began to vanish. The intravenous injection of 1 × 106
hASCs was able to completely abolish thermal hyperalgesia
starting one day after the injection [46]. The effects of
hASCs on thermal hyperalgesia seem to be more potent
than those of NSC [10]. In fact, as shown in Figure 1(a),
the withdrawal thresholds of hASC treated mice were overall
higher than those of NSC treatedmice, and 7 days after hASC
injection thermal hyperalgesia was completely abolished,
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while, for allodynia, a comparable effect of the two cells is
evident (Figure 1(b)). The effect on pain relief well correlates
with a general systemic and injured nerve localized anti-
inflammatory effect of hASC. In fact, a significant increase
of IL-10 serum concentration is already evident 1 day after
hASC treatment; moreover at nerve site, the protein levels
of IL-1, increased by the pathology, appeared normalized 1
day after the hASC injection, while the anti-inflammatory
cytokine IL-10, decreased by CCI, gradually increased until
reaching levels 3 times higher over control group [46]. The
dose response effect, described for pain, was also evident for
cytokines, indicating a clear correlation between pain relief
and anti-inflammatory effect of hASCs. If we compare the
effect on cytokines of hASC versus NSC, it is clear that the
big difference between these two cell types regard their effect
on IL-10. No changes at nerve site on IL-10 protein is evident
seven days after NSC injection while, at the same time, IL-10
is strongly increased by hASC [46].We assume that this effect,
together with the general systemic anti-inflammatory one,
could be responsible of the stronger antihyperalgesic effect
of hASC. Besides the effects induced by hASC at nerve site
we described also a normalization of the spinal cord iNOS
protein level which is evident with a full neuropathic pain
recovery. This paper clearly suggests a possible therapeutic
use of hASC for neuropathic pain treatment.
These same cells and hATSCs, human adipose tissue-
derived stem cells treated in vitro with ZnO shell nanoparti-
cles in order to improve stem cell function, were recently used
by In Choi et al. [49]; these cells, intrathecally injected, were
able to reduce the pain consequent to a spinal cord injury by
increasing the paw withdrawal thresholds to mechanical and
thermal stimuli.
3.3. Umbilical Cord-Derived Mesenchymal Stem Cells (UC-
MSC). Human umbilical cord (UC) is a promising source
of mesenchymal stem cells (MSC) and is nowadays under
researchers’ investigation. UC contains two umbilical arteries
(UCAs) and one umbilical vein (UCV), both embedded
within a specific mucous connective tissue, known as Whar-
ton’s jelly (WJ), which is covered by amniotic epithelium.
MSC can be isolated from all these compartments by using
different techniques; today it is still unclear which one is the
best compartment in UC for clinical use. UC-MSC possess
a gene expression profile similar to that of embryonic stem
cells, but their collection procedure is considered ethically
correct, and they are characterized by a faster self-renewal
rate than MSC isolated, for example, from bone marrow.
Moreover they have other attractive advantages which are
summarized here: (1) a noninvasive collection procedure for
autologous or allogeneic use; (2) a lower risk of infection;
(3) a low risk of developing teratoma; (4) multipotency, and
(5) low immunogenicity with a good immunosuppressive
ability [50]. Roh and colleagues [51] recently investigated
the therapeutic effect of transplanting human umbilical
cord blood-derived mesenchymal stem cells (hUCB-MSC)
or amniotic epithelial stem cells (hAESCs) on SCI-induced
mechanical allodynia and thermal hyperalgesia in T13 spinal
cord hemisected rats. Two weeks after SCI, hUCB-MSC or
hAESC were transplanted around the spinal cord lesion site,
and behavioral tests were performed; moreover, immuno-
histochemical and Western blot analyses were performed
to evaluate possible therapeutic effects on SCI-induced
inflammation and the nociceptive-related phosphorylation
of the NMDA NR1 receptor subunit. The authors described
only a weak antiallodynic effect of hUCB-MSC if compared
to that of hAESCs and no effect on thermal hyperalgesia
of either cell type. The antiallodynic effect of hAESCs is
associated with a decrease in spinal cord microglia activity
and NMDA receptor NR1 phosphorylation. In contrast to the
weak efficacy of hUCB-MSC on pain symptoms, the group
of Yang [52] using HUMSCs from Wharton’s jelly of the
umbilical cord transplanted into the spinal cord described a
beneficial effect for wound healing and locomotor recovery
after spinal cord injury in rats suggesting a potential use of
these cells if not for pain at least for motor recovery.
4. Bone Marrow Derived Mononuclear Cells
An improvement in experimental neuropathic pain treat-
ment was also obtained using other types of cells isolated
from bone marrow and in particular by using bone marrow
derived mononuclear cells. A paper of Klass et al. [53]
described that the infusion (1 × 107, i.v.) of rat marrow
mononuclear cells, containing mixed stem cell populations,
10 days after rat CCI, was able to induce neuropathic pain
recovery (both hyperalgesia and allodynia). The authors did
not investigate into the mechanisms involved in such mod-
ulations. Freshly isolated rat bone marrow-derived mononu-
clear cells (BM-MNCs) were also used for contrasting dia-
betes neuropathy induced in rats by STZ [54]. Cells injected
into the hind limb skeletal muscles two weeks after STZ
were able to ameliorate mechanical hyperalgesia and cold
allodynia in the BM-MNC-injected side. Furthermore, the
slowed sciatic nerve conduction velocities (MNCV/SNCV)
and decreased sciatic nerve blood flow in diabetic rats
were improved in the BM-MNC-injected side. BM-MNC
transplantation further decreased mRNA expression of NT-3
and number of microvessels in the hind limb.
5. Conclusions
In recent years, the possibility to apply stem cells for the
treatment of neuropathic pain has attracted much attention,
as demonstrated by the increasing number of preclinical
studies in the literature (Table 1).
In whole the preclinical data here reported suggest
positive effects of stem cells for relieving experimental neu-
ropathic pain. An interesting point that emerges from the
detailed analysis of the preclinical data is that peripheral
neuropathic pain seems to be more responsive to stem cell
treatment than pain arising from central lesion such as
spinal cord injury. Moreover in SCI, stem cell treatment is
not always able to positively and contemporarily affect both
pain symptoms and motor recovery, indicating that different
mechanisms can underlie the different effects.
It is important to underline that one of the main aspects
concerning stem cells usage is both their fast onset and long
lasting effect on pain relief; a single administration of cells is
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Table 1: Stem cells used for experimental neuropathic pain treatment.
Cell source Delivery site Number of cells Model of NPand species Effect on pain Author and year
Neural stem cells
NSC (mouse) Intravenous 1, 2, 3 × 106 CCI (mouse)
Improvement of thermal
hyperalgesia and
mechanical allodynia
Franchi et al.,
2012 [10]
NSC (rat) Intrathecal 1 × 106 CCI (rat)
Improvement of thermal
and mechanical
hyperalgesia
Xu et al., 2013
[21]
NSC + OEC (rat) Injury site 3 × 105 SCI (rat)
Cotransplantation
improves sensory
function
Luo et al., 2013
[22]
NPC (mouse) Injury site 4 × 105 SCI (rat) No effect on pain(allodynia)
Karimi-
Abdolrezaee et
al., 2010 [23]
NPC (rat) Injury site 1 × 105 SCI (rat) Induction of allodynia Hofstetter et al.,2005 [24]
NSC (mouse) Injury site 1 × 105 SCI (rat)
Induction of thermal
and mechanical forelimb
allodynia
Macias et al.,
2006 [25]
Bone marrow
mesenchymal stem cells
MSC (rat) Intraganglionic(DRG) 2 × 10
5 SLNC (rat)
Prevention of
mechanical and thermal
allodynia
Musolino et al.,
2007 [39]
MSC (rat) Injection in the hindlimb skeletal muscle 1 × 10
6 STZ-induced
diabetes (rat)
Improvement of
hypoalgesia
Shibata et al.,
2008 [41]
MSC (human) Lateral cerebralventricle 5 × 10
4 SNI (mouse)
Improvement of
mechanical allodynia
and thermal
hyperalgesia
Siniscalco et al.,
2010 [43]
MSC (human) Intravenous 2 × 106 SNI (mouse)
Improvement of thermal
hyperalgesia and
mechanical allodynia
Siniscalco et al.,
2011 [44]
MSC2 (human) Intraperitoneal 5 × 105, 1 × 106
STZ-induced
diabetes
(mouse)
Improvement of
mechanical allodynia
and heat hypoalgesia
Waterman et al.,
2012 [45]
Adipose tissue
derived-mesenchymal
stem cells
ASC (human) Intravenous 5 × 105, 1 × 106 CCI (mouse)
Improvement of thermal
hyperalgesia and
mechanical allodynia
Sacerdote et al.,
2013 [46]
ATSC/core shell
particle-treated
ATSC
(human)
Intrathecal Not indicated SCI (mouse)
Improvement of
mechanical allodynia
and thermal
hyperalgesia
In Choi et al.,
2013 [49]
Umbilical cord
mesenchymal stem cells
UCB-MSC
(human) Injury site 1 × 10
6 SCI (rat) Tendency to reducemechanical allodynia
Roh et al., 2013
[51]
(HUMSCs)
isolated from
Wharton’s jelly
(human)
Injury site 5 × 105 SCI (rat) Locomotor recovery Yang et al., 2008[52]
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Table 1: Continued.
Cell source Delivery site Number of cells Model of NPand species Effect on pain Author and year
Bone marrow derived
mononuclear cells
Marrow
mononuclear cells
(rat)
Intravenous 1 × 107 CCI (rat)
Improvement of thermal
and mechanical
allodynia
Klass et al., 2007
[53]
BM-MNC (rat)
Injected into 10 points
in the unilateral
femoral quadriceps,
femoral biceps, and
soleus muscles
1 × 106 STZ-induceddiabetes (rat)
Improvement of
mechanical and thermal
allodynia
Naruse et al.,
2011 [54]
in fact able to induce an antiallodynic and antihyperalgesic
effect which persists for long time, as it is still present up
to 90 days after injection [44]. Generally, the conventional
[8] and the newer pharmacological strategies [55, 56] for
neuropathic pain treatment need a chronic treatment to be
effective. The analgesic success of the commonly available
drugs is often limited by side effects that appear increasing
the administration dose or by the development of tolerance
[8]. Moreover, in order to successfully approach this type
of pain, patients often are treated with a combination of
drugswith differentmechanisms of action, increasing the risk
of drug interaction and often reducing patient’s compliance
[9]. A more long lasting effect for some type of neuropathic
pain such as low back pain or disk herniation can eventually
be achieved by surgical approaches or epidural treatment,
obviously exposing the patients to all the risks of the surgery.
The clamorous effect of stem cells on pain relief in the
preclinical tests may be related to their capacity to not only
control pain as a symptom, but to act as disease modifier
on the mechanisms at the basis of the development and
maintenance of pain condition, for example, modulating
the neuroimmune component which plays a relevant role
in neuropathic pain. Despite these positive and encourag-
ing considerations, there are many issues that need to be
addressed and solved for a successful clinical translation.
These points are well summarized in the review by Bonfield
and Caplan [57] and include the classification of the cells,
their efficacy and potency, their mode of administration,
their dosage and their source, together with the final goal
of the analysis, and the tracking of the stem cell. Among
these, as emerged in this review, the route of administration
of stem cells represents an important variable which may
also influence the choice of the final number of cells to be
injected. Strategies for local stem cell delivery can be applied
to the treatment of well localized lesions but are, however,
described to increase risks and side effects such as bleeding
and tissue injury [58]; certainly, froma clinical point of view, a
systemic delivery is attractive, given the broad biodistribution
and easy access. On the other hand, we have to point out
that this route is, in some cases, associated with a passive
cell entrapment within tissues that do not represent the main
target of treatment, which may potentially lead to unwanted
effects andmay be eventually associated to a reduced effect of
the cells. The homing of stem cells after a systemic injection
represents in fact a much debated topic. In our first paper we
described the capacity of stem cells to specifically reach the
damaged nerve [10]. Although we observed a low transplant
efficiency, we did not find the cells into other critical tissues
such as lungs. AlsoMaione’s group [44] reported the ability of
MSC to home central nervous system areas critically involved
in NP signaling describing only a scarce presence of stem
cell in the lungs. In general, however, other papers report
a marked lung first passage effect of the cells which limits
the number of cells which can reach the area of injury [59–
61]. Overall the literature agrees with the general idea that
stem cells, even in a limited number, can interact with the
host cells and orchestrate a long lastingmodulation resulting,
most of the times, in a final beneficial therapeutic effect
[10, 44, 58]. Another strictly related question is the toxicity
and the possible malignant transformation and cytogenetic
aberrations of stem cells. The literature quite agrees on the
safety of stem cells [62, 63] but by a careful analysis of the
preclinical papers reported here, it emerges that this aspect
has not been specifically or adequately considered. In our
work [46] we injected different doses of hASC reaching the
highest dose of 6 × 106 cells/mice and we did not register
any macroscopic adverse effect: no animal died or changed
its habits/behaviour and no side effects have been observed.
The safety of a similar dose of hASC intravenously infused in
animals and humans was also described by Ra and colleagues
[64]; the authors did not register any side effect or tumor
mass formation in the three months after cell infusion. Also
the paper by Waterman et al. [45] described no premature
mortality or morbidity due to MSC treatment and the
necropsy of the cell treated animals revealed no macroscopic
pathology of any of the major organs. In contrast, Djouad
and colleagues [65] described an increase of tumor formation
in animals likely due to the immunosuppressive effects of
MSC, rather than to a direct transformation of stem cells in
tumor cells. Even though, as discussed, there are still many
open points that need better understanding, a clear trend to
clinical use of stem cells also in treating pain is apparent, as
demonstrated by a very recent and scientifically sound paper
[66] that reported a preliminary human study in which the
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autologous administration of adipose derived stem cells in
the facial tissue was able to attenuate orofacial neuropathic
pain symptoms. The cells were injected perineurally directly
into the center of origin of pain and in the adjacent pain field
of the affected branches of the trigeminal nerve. The effect
of the treatment was evident 6 months after cell injection
and cells were described to be safe, well tolerated by the
patients, and accompanied by a significant reduction of
analgesic drug doses. What is clear is that the research on
stem cells is evolving; newly discovered populations of stem
cells begin to be characterized and used in the regenerative
medicine. The bioactive molecules that can be released by
these same stem cells are starting to be identified and are
likely effectors/candidates for the therapeutic effect. As an
example the beneficial role of the medium conditioned by
MSC for improving motor recovery was recently described
[67]. Finally several reports indicate that the regenerative
[68] and immunomodulatory [69] effects of MSC can be
partially reproduced by themicrovesicles (MVs) that are shed
by activated MSC and that can be isolated from their culture
medium [69]. On the basis of these considerations it is to be
expected that the panorama of neuropathic pain treatment
will change again shortly.
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